Canada Bought 64 Senior Researchers for $541 Million. The Number That Matters Is 5,800 to 2,100.

The Announcement

On August 27, 2026, Industry Minister Mélanie Joly named the first 64 recipients of the Eddie Goldenberg Research Chairs of Canada. Forty-eight of them — three-quarters — are leaving American institutions, among them Harvard, Yale, MIT, Stanford, Duke and Michigan. The cohort spans 13 countries.

The money is specific. $504 million over eight years funds the 64 chairs: sixty of them at either $500,000 or $1 million a year, and four Distinguished Research Chairs at $1.5 million a year. A further $37 million funds 63 Canada Impact+ Emerging Leaders at $100,000 a year for six years. Combined, roughly $541 million. It sits inside the $1.7-billion Canada Global Impact+ Research Talent Initiative announced in December 2025, which targets 100 chairs and, eventually, 1,000 researchers.

The recruits go to 21 institutions, 54 of them to U15 universities. UBC took nine, the University of Ottawa seven, McGill and the University of Toronto six each, McMaster five. Most start in July 2027.

The names are not obscure. Sara Seager, the MIT astrophysicist, goes to Toronto. So do Tanya Berger-Wolf from Ohio State, Shu Jiang from Washington University in St. Louis, and Michelle Arkin from UCSF. UBC took Peter Caravan after two decades at Massachusetts General and Harvard Medical School, along with Curtis Huttenhower from Harvard and Kathryn Whitehead from Carnegie Mellon. McMaster pulled James LeBeau out of MIT and two radiopharmaceutical researchers out of Alabama-Birmingham, at $8 million over eight years each.

Sixty-Four People Is Not a Brain Drain

Now the correction the coverage mostly skips. Sixty-four researchers is a small number. The United States employs hundreds of thousands of academic researchers. Losing five dozen senior faculty over two hiring years is not a collapse, and $541 million is a rounding error against American federal R&D spending.

Treating this as the injury misreads it. It is a symptom, and a cheap one to produce.

What makes it worth attention is the selection. These are not junior hires. They are established investigators with running labs, funded programmes and graduate students, and each one leaves behind an ecosystem that took a decade to assemble and does not relocate cleanly. Canada is not buying headcount. It is buying the top of a distribution, at a moment when it can.

The Pipeline Number

Here is the arithmetic that actually determines what happens next, and it has nothing to do with 64 people.

The FY2027 President’s Budget Request asks for $3.96 billion for the National Science Foundation, against $8.75 billion enacted for FY2026 — a 55% reduction. Research and Related Activities would fall from $7.18 billion to $3.41 billion. The computing directorate would drop 63%.

Translated out of dollars and into people: that budget would fund roughly 2,100 research grants against 5,800 in FY2025, at a 7% success rate, supporting 94,100 people versus 305,400.

Two hundred thousand fewer people supported. That is the number the phrase “brain drain” should attach to, and it dwarfs 64 by three orders of magnitude.

One critical qualifier, because it is where a lot of commentary goes wrong: this is a request, not an enacted cut. Congress rejected near-identical proposals in the FY2026 cycle and largely held nondefense R&D flat; the Senate specifically declined to gut NASA, NSF and NIST. The FY2027 request is a proposal that has already failed once.

The executed damage is real but smaller and messier. The Brennan Center’s accounting puts roughly $2.3 billion in NIH grants frozen or cancelled during 2025 across nearly 2,500 awards, including 383 clinical trials, plus about $700 million at NSF, with around $1.4 billion still frozen or cancelled into early 2026.

What Canada Is Actually Buying

Canada is not outbidding the United States. At $1 million a year, an Eddie Goldenberg chair is a good package, not an extraordinary one — a well-funded American lab can exceed it.

What Canada is selling is an eight-year commitment in writing. That is the product. When the binding constraint on a research career stops being salary and becomes the question of whether your grant survives the next budget cycle, a mid-tier offer with a guaranteed horizon outcompetes a richer offer with an unknown one. Ottawa did not need to win an auction. It needed to be the party not holding a re-authorisation fight.

The behavioural data points the same way, with a caveat. Nature’s analysis of its own jobs-board traffic found US-based scientists submitted 32% more applications abroad in the first quarter of 2025 than a year earlier, with applications to Canadian postings up 41%. A Nature poll found 75% of US respondents considering leaving — though that poll is self-selected and reads better as intent among the alarmed than as a population estimate. Separately, new international student enrolment fell 17% in autumn 2025, which matters more, because that is the intake end of the pipeline rather than the exit.

What to Watch

• Intake 2 of the programme. Thirty-six chairs remain of the 100. If the US share stays near three-quarters, the flow is structural. If it falls, this was a one-off clearing of people already looking.
• FY2027 appropriations, not the budget request. Congress has refused these cuts once. Whether it does so again is the single variable that decides whether 64 becomes 640.
• Whether American institutions counter-offer. Almost none of the departures reported so far involved a retention fight, which suggests US universities are not confident enough in their own funding to make multi-year commitments either.

If you are trying to read where research capacity is heading, stop counting departures. Count grants. The 64 chairs are a lagging indicator of decisions made in 2025; NSF’s award count and the international enrolment figures are the leading ones, and both report before the next cohort of professors packs a moving truck.